Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginReturn on AssetsReturn on Capital EmployedReturn on Sales

ProQR Therapeutics N.V (PRQR) EBIT Margin: 2021-2025

Historic EBIT Margin for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -381.89%.

  • ProQR Therapeutics N.V's EBIT Margin fell 17091.00% to -381.89% in Q3 2025 from the same period last year, while for Sep 2025 it was -276.77%, marking a year-over-year decrease of 14142.00%. This contributed to the annual value of -161.18% for FY2024, which is 32790.00% up from last year.
  • Latest data reveals that ProQR Therapeutics N.V reported EBIT Margin of -381.89% as of Q3 2025, which was down 19.86% from -318.60% recorded in Q2 2025.
  • ProQR Therapeutics N.V's 5-year EBIT Margin high stood at -45.87% for Q2 2024, and its period low was -8,943.97% during Q1 2021.
  • Moreover, its 3-year median value for EBIT Margin was -223.04% (2025), whereas its average is -377.39%.
  • Examining YoY changes over the last 5 years, ProQR Therapeutics N.V's EBIT Margin showed a top increase of 769,530bps in 2022 and a maximum decrease of 113,034bps in 2022.
  • ProQR Therapeutics N.V's EBIT Margin (Quarterly) stood at -7,622.59% in 2021, then surged by 577,537bps to -1,847.22% in 2022, then skyrocketed by 168,041bps to -166.81% in 2023, then crashed by 4,923bps to -216.04% in 2024, then tumbled by 17,091bps to -381.89% in 2025.
  • Its EBIT Margin was -381.89% in Q3 2025, compared to -318.60% in Q2 2025 and -223.04% in Q1 2025.